Notice: This company has been marked as potentially delisted and may not be actively trading. Myovant Sciences (MYOV) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Global Prostate Cancer Diagnostics Market to Observe Stunning Growth at a CAGR of ~12% by 2030 | DelveInsightSeptember 25, 2024 | finance.yahoo.comThe Scientific Establishment Is Turning 'Science' Into a Dogmatic Tool of Oppression | OpinionSeptember 12, 2024 | newsweek.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | msn.comGynecology Collaboration, R&D, and Licensing Deals Trends Report 2024May 7, 2024 | finance.yahoo.comWorld Metastatic Prostate Cancer Drug Landscape Research Report 2024: Comprehensive Insights about 90+ Companies and 110+ Pipeline DrugsApril 18, 2024 | uk.finance.yahoo.com2024 Could Be Women’s Health’s Long-Awaited, Much-Needed Standout YearJanuary 15, 2024 | forbes.comGlobal $67B+ Women's Health Market Landscape 2024-2030: Analysis by Age, Application and RegionJanuary 11, 2024 | finance.yahoo.comReAlta Life Sciences Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology ExecutivesJanuary 3, 2024 | finance.yahoo.comVivek Ramaswamy wins legal battle over bid to force him to give evidence in multi-million dollar court case after GOP long-shot candidate claimed he was too busy campaigning to ...December 28, 2023 | dailymail.co.ukMetastatic Castration-Sensitive Prostate Cancer Market to Skyrocket at Astounding 22% CAGR During the Study Period (2019-2032), assesses DelveInsightDecember 8, 2023 | finance.yahoo.comNCCN Announces Funding for Advanced Prostate Cancer Research ProjectsNovember 21, 2023 | markets.businessinsider.comMyovant Sciences, Ltd. (MYOV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsOctober 22, 2023 | barrons.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOVSeptember 26, 2023 | benzinga.com4D Molecular Therapeutics Appoints Uneek Mehra Finance & Business ChiefSeptember 12, 2023 | marketwatch.comVivek Ramaswamy claims he is too busy campaigning to give evidenceAugust 29, 2023 | msn.com2024 Presidential candidate Vivek Ramaswamy trying to duck legal battle over his biotech empireAugust 29, 2023 | msn.comEXCLUSIVE: Vivek Ramaswamy claims he is too busy campaigning for President to give evidence in multi-million dollar court caseAugust 28, 2023 | msn.comVivek Ramaswamy cites campaign to duck deposition in buyout suitAugust 28, 2023 | msn.comBill Ackman Tells Vivek Ramaswamy How To Run For PresidentAugust 24, 2023 | msn.comUterine Fibroids Treatment Global Market Report 2023August 24, 2023 | finance.yahoo.comPresidential Hopeful Ramaswamy Predicts US Recession In 2024August 21, 2023 | benzinga.comHormone Therapy Global Market Report 2023July 4, 2023 | uk.finance.yahoo.comHealth in Her HUE to Host Discussion Around Fibroids Awareness and Launch the Fibroids-focused Care Squad Program during Fibroid Awareness MonthJune 26, 2023 | finance.yahoo.comAntibacterial Drugs Market to Reach US$ 62 Billion by 2031 | Fact.MR ReportJune 22, 2023 | benzinga.comWomen's Health Market to Reach $63.02 Billion by 2030: Grand View Research, Inc.May 18, 2023 | finance.yahoo.comMyovant Sciences and Evidation Announce Survey Results of Unseen Burdens at Work and School of Individuals with Endometriosis and/or Uterine FibroidsMay 17, 2023 | finance.yahoo.comEndometriosis Treatment Drugs Market Top Competitors and Prediction Till 2030May 16, 2023 | marketwatch.comMetastatic Prostate Cancer Treatment Market Size: Growth Dynamics from 2023 to 2031May 10, 2023 | marketwatch.comMenstrual Cramps Treatment Market worth growing 4.0% at a CAGR by 2027May 8, 2023 | marketwatch.comGlobal "Metastatic Prostate Cancer Treatment Market" Growth and Outlook till 2023-2030May 8, 2023 | marketwatch.com8-K: Day One Biopharmaceuticals, Inc.May 2, 2023 | marketwatch.comProstate Cancer Treatment Market Business Expands Quickly and Will Occupy Over USD 12,152 Million by 2030April 27, 2023 | marketwatch.comEndometriosis Market Growth by 2031April 26, 2023 | marketwatch.comMyovant Sciences won 3 drug approvals and got bought out. Now it's cutting nearly 100 jobs.April 25, 2023 | bizjournals.comLeading National Prostate Cancer Nonprofit Announces Return of Annual Run/Walk SeriesApril 25, 2023 | finance.yahoo.comMyovant Sciences (NYSE:MYOV) Receives New Coverage from Analysts at StockNews.comStockNews.com started coverage on Myovant Sciences in a report on Tuesday. They set a "hold" rating on the stock.April 11, 2023 | marketbeat.comSumitomo Pharma Subsidiary Companies in the U.S., Including Sumitovant and its Wholly Owned Subsidiaries, to Combine and Form Sumitomo Pharma AmericaApril 3, 2023 | finance.yahoo.comMyovant Sciences (NYSE:MYOV) Now Covered by Analysts at StockNews.comStockNews.com initiated coverage on Myovant Sciences in a report on Monday. They issued a "hold" rating for the company.April 3, 2023 | marketbeat.comEndometriosis Global Market Report 2022: Rise in Demand for Novel Drugs and Hormonal Therapies Bolsters SectorMarch 29, 2023 | finance.yahoo.comEndometriosis Treatment Drugs Market Growth By 2031March 27, 2023 | marketwatch.comMyovant Sciences (NYSE:MYOV) Coverage Initiated at StockNews.comStockNews.com assumed coverage on Myovant Sciences in a research report on Sunday. They set a "hold" rating on the stock.March 26, 2023 | marketbeat.comHennion & Walsh Asset Management Inc. Sells 141,504 Shares of Myovant Sciences Ltd. (NYSE:MYOV)Hennion & Walsh Asset Management Inc. lessened its stake in Myovant Sciences Ltd. (NYSE:MYOV - Get Rating) by 52.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 126,398 shares of the company's stock after selling 141,504March 21, 2023 | marketbeat.comMyovant Sciences (NYSE:MYOV) Now Covered by StockNews.comStockNews.com assumed coverage on shares of Myovant Sciences in a research note on Saturday. They set a "hold" rating on the stock.March 18, 2023 | marketbeat.comMyovant Sciences Ltd. (NYSE:MYOV) Major Shareholder Chemical Co. Ltd. Sumitomo Acquires 51,599,200 SharesMyovant Sciences Ltd. (NYSE:MYOV - Get Rating) major shareholder Chemical Co. Ltd. Sumitomo acquired 51,599,200 shares of the business's stock in a transaction dated Friday, March 10th. The shares were bought at an average price of $27.00 per share, with a total value of $1,393,178,400.00. Following the transaction, the insider now directly owns 45,798,176 shares in the company, valued at approximately $1,236,550,752. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.March 10, 2023 | marketbeat.comGlobal GnRH Receptor Antagonists Market research Report with Analysis 2023 To 2028March 10, 2023 | marketwatch.comTrading was temporarily halted for "MYOV" at 08:03 AM with a stated reason of "Merger Effective."March 10, 2023 | marketbeat.comAs a two-time CEO, Lynn Seely is putting more cracks in the glass ceilingMarch 3, 2023 | bizjournals.comMyovant Sciences Ltd. (NYSE:MYOV) Shares Acquired by ExodusPoint Capital Management LPExodusPoint Capital Management LP increased its position in shares of Myovant Sciences Ltd. (NYSE:MYOV - Get Rating) by 19.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 83,247 shares of the company's stock after acquiring an adFebruary 23, 2023 | marketbeat.comGlobal Uterine Fibroids Treatment Market Report to 2027: Players Include Myovant Sciences, Gynesonics, Medtronic and Boston ScientificFebruary 9, 2023 | finance.yahoo.comMyovant Sciences, Inc.: Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022January 29, 2023 | finanznachrichten.de Get Myovant Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MYOV and its competitors with MarketBeat's FREE daily newsletter. Email Address 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here MYOV Media Mentions By Week MYOV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MYOV News Sentiment▼0.000.60▲Average Medical News Sentiment MYOV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MYOV Articles This Week▼00▲MYOV Articles Average Week Get Myovant Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MYOV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ITCI News ROIV News MDGL News JAZZ News VKTX News LEGN News ASND News ELAN News CYTK News BPMC News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:MYOV) was last updated on 11/13/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredYou just voted for a financial crisisI’d like to share with you my #1 high-conviction stock to buy before Inauguration Day… and details on the asse...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myovant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Myovant Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
